Login
$BVS
$10.46 -$0.20 (1.88%) Live

$BVS 8-K SEC Filings

Filed On Filing
02 Nov 2026 8-K: Results of Operations and Financial Condition

DURHAM, NC – November 2, 2026 – Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today reported financial results for the three and nine months ended September 26, 2026.

05 Aug 2026 8-K: Results of Operations and Financial Condition; Other Events

DURHAM, NC – August 5, 2026 – Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today reported financial results for the three and six months ended June 27, 2026.

04 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

Bioventus, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) on June 3, 2026. A total of 75,279,174 shares (the “Shares”) of both Class A common stock and Class B common stock (collectively, th...

21 May 2026 8-K: Regulation FD Disclosure

On April 16, 2026, the U.S. Food and Drug Administration (“FDA”) issued a final order reclassifying non-invasive bone growth stimulators, including the Company’s Exogen® Ultrasound Bone Healing System, from Class III to Class II devices....

06 May 2026 8-K: Results of Operations and Financial Condition

DURHAM, NC – May 6, 2026 – Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three months ended March 28, 2026.

05 Mar 2026 8-K: Results of Operations and Financial Condition

DURHAM, NC — March 5, 2026 — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced fourth quarter and full-year financial results for the year ended December 31, 2...

17 Nov 2025 8-K: Departure/Election of Directors or Officers; Compensation

On November 14, 2025, the Board of Directors (the “Board”) of Bioventus Inc. (the “Company”) appointed Ajay Dhankhar, PhD, to the Board as a Class II director effective on November 14, 2025. Dr. Dhankhar will serve for a term ending at t...

04 Nov 2025 8-K: Results of Operations and Financial Condition

DURHAM, NC – November 4, 2025 – Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three and nine months ended September 27, 2025.

06 Aug 2025 8-K: Results of Operations and Financial Condition

DURHAM, NC – August 6, 2025 – Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three and six months ended June 28, 2025.

04 Aug 2025 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

WELLS FARGO SECURITIES, LLC, DNB MARKETS, INC., JPMORGAN CHASE BANK, N.A.

31 Jul 2025 8-K: Other Events

DURHAM, N.C., July 30, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, announced today a significant milestone with the U.S. Food and Drug Administration (FDA) 510(k) clearances f...

04 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

Bioventus, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”) on June 3, 2025. A total of 73,619,248 shares (the “Shares”) of both Class A common stock and Class B common stock (collectively, th...

06 May 2025 8-K: Results of Operations and Financial Condition

DURHAM, NC – May 6, 2025 – Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three months ended March 29, 2025.

11 Mar 2025 8-K: Results of Operations and Financial Condition

DURHAM, NC — March 11, 2025 — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced fourth quarter and full-year financial results for the year ended December 31, ...

03 Jan 2025 8-K: Completion of Acquisition or Disposition of Assets; Other Events

DURHAM, N.C., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has successfully completed the divestiture of its Adv...

05 Nov 2024 8-K: Results of Operations and Financial Condition

DURHAM, NC – November 5, 2024 – Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three and nine months ended September 28, 2024.

04 Oct 2024 8-K: Entry into a Material Definitive Agreement; Other Events

ANNEX I Balance Sheet Rules and Working Capital Illustrative Example

06 Aug 2024 8-K: Results of Operations and Financial Condition

DURHAM, NC – August 6, 2024 – Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three and six months ended June 29, 2024.

19 Jul 2024 8-K: Other Events

As previously disclosed, on January 12, 2023, Bioventus Inc. (the “Company” or “Bioventus”) and certain of its current and former directors and officers were named as defendants in a putative class action lawsuit filed in the Middle Dist...

21 Jun 2024 8-K: Entry into a Material Definitive Agreement

This Amendment No. 1 to Stockholders Agreement (this “Amendment”) is entered into as of June 19, 2024 by and among (i) Bioventus Inc., a Delaware corporation (the “Company”), (ii) Bioventus LLC, a Delaware limited liability company (“Bio...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support